For Public
An Innovative Simple Blood Test to Detect Colorectal Cancer Early
Colorectal cancer is a major health concern worldwide. Early detection is crucial for better treatment outcomes. ColonAiQ is a groundbreaking test that makes it easier to detect colorectal cancer early. Here’s what you need to know:
What is ColonAiQ®?
- Non-Invasive Test: ColonAiQ uses a simple blood test to detect signs of colorectal cancer.
- Advanced Technology: It analyzes tiny DNA changes in your blood linked to cancer.
Why is Early Detection Important?
- Better Treatment: Detecting cancer early increases the chances of successful treatment.
- Increased Survival Rates: Early detection can significantly improve survival rates
How Does ColonAiQ® Work?
- Sample Collection: A small blood sample is taken.
- DNA Extraction: Special techniques are used to isolate DNA from the blood.
- DNA Analysis: The DNA is examined for specific changes (methylation) linked to colorectal cancer.
Key Benefits of ColonAiQ®
- High Accuracy: ColonAiQ has shown to be highly accurate in detecting colorectal cancer.
- Sensitivity: 86-89% (ability to correctly identify those with cancer)
- Specificity: 92-93% (ability to correctly identify those without cancer)
- Early Detection: More effective in finding cancer in its early stages compared to traditional methods.
ColonAiQ® vs. CEA (Carcinoembryonic Antigen)
- Overall Accuracy: ColonAiQ® 88.3%, CEA 59.7%
- Early Stage Detection: ColonAiQ® 85.7%, CEA 28.6%
ColonAiQ® vs. FIT (Fecal Immunochemical Test)
- Overall Accuracy: ColonAiQ® 85.1%, FIT 72.0%
- Early Stage Detection: ColonAiQ® 78.3%, FIT 52.2%
Additional Benefits
- Relapse Monitoring: ColonAiQ® can also help monitor patients for cancer relapse after treatment, providing an early warning if cancer returns.
ColonAiQ® vs. SEPT9
- Overall Accuracy: ColonAiQ® 85.5%, SEPT9 38.2%
- Early Stage Detection: ColonAiQ® 91.7%, SEPT9 16.7%
Where Has ColonAiQ® Been Tested?
- Top Hospitals: ColonAiQ has been validated in leading hospitals and medical centers in China, including Fudan University Shanghai Cancer Center and Zhongshan Hospital.
- Clinical Trials: It has been tested in multiple studies with large sample sizes, proving its reliability and effectiveness.
Conclusion
ColonAiQ offers a revolutionary, non-invasive way to detect colorectal cancer early and accurately. By choosing ColonAiQ, you are opting for a test that can save lives through early detection and improved treatment outcomes.
For more information about ColonAiQ, talk to your healthcare provider.
- Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 68(6), 394–424. https://doi.org/10.3322/caac.21492
- Singapore Cancer Network (SCAN) guidelines for Systemic therapy of colorectal cancer. (2015). Annals, Academy of Medicine, Singapore/Annals of the Academy of Medicine, Singapore, 44(10), 379–387. https://doi.org/10.47102/annals-acadmedsg.v44n10p379
https://doi.org/10.1053/j.gastro.2021.08.054 - Cai, G., Cai, M., Feng, Z., Liu, R., Liang, L., & Zhou, P. (2021). A Multilocus Blood-Based Assay Targeting Circulating Tumor DNA Methylation Enables Early Detection and Early Relapse Prediction of Colorectal Cancer. Gastroenterology, 161(6), 2053-2056.e2. https://doi.org/10.1053/j.gastro.2021.08.054
